Measuring plasma emicizumab levels is not required for therapy. However, a drug level may be helpful in specific medical incidences, such as confirmation of compliance. Monitoring can also be beneficial in breakthrough bleeding, situations that require an on-demand coagulation factor, or antibody monitoring.

A noteworthy consideration while treating patients on emicizumab is the drugâ€™s effect on laboratory testing.

Clinicians need to be aware of assay interference when ordering FVIII activity or inhibitor titers in a patient taking emicizumab

Clinicians can use the Haemophilia Quality of Life Questionnaire for Adults (Haem-A-QoL) to evaluate health-related quality of life (HRQoL) in patients with hemophilia who are on treatment with emicizumab.